Logo

Exact Sciences

Exact Sciences Continues M&A Strategy to Reach Further Into Cancer Dx Market
Premium

The company recently acquired PFS Genomics, which has developed a test to determine the necessity of radiotherapy for breast cancer patients.

Exact Sciences Reports 16 Percent Q1 Revenues Rise, Acquires PFS Genomics for $30.6M

The company said screening revenues, from Cologuard tests and Biomatrica products, rose 10 percent year over year during the quarter.

Prostate Cancer Study Shows Oncotype DX GPS Test Accurately Measures Long-Term Outcomes
Premium

The 20-year study showed the test provided an accurate assessment of the risk of long-term metastases and mortality for patients with localized prostate cancer. 

Exact Sciences Sketches Out Strategy for End-to-End Cancer Testing With Ashion Acquisition
Premium

The company is getting ready to offer cancer patients every type of molecular cancer diagnostics, including testing for minimal residual disease.

Exact Sciences Q4 Revenues up 58 Percent; Company to Acquire Ashion Analytics From TGen

Exact's planned acquisition of Ashion, a sequencing lab based in Arizona, builds on the company's licensing of the TARDIS liquid biopsy technology from TGen in January.

Jan 15, 2021

People in the News: Broad Institute's Eric Lander Named White House Science Advisor; More

Jan 14, 2021

JP Morgan Healthcare Conference 2021, Day 3: Exact Sciences, Danaher, NanoString, Bio-Techne, More

Jan 11, 2021

Multi-Cancer Molecular Screening Assays Primed for Clinical Implementation in 2021
Premium

Jan 11, 2021

Exact Sciences Reports Preliminary Q4 Revenues Up About 58 Percent

Dec 28, 2020

M&A Deals in MDx/Omics Research Tools Space Fall 13 Percent in 2020
Premium

Dec 10, 2020

Exact Sciences Oncotype DX Identifies Postmenopausal Breast Cancer Patients Who Can Forgo Chemo
Premium

Nov 17, 2020

Diagnostics Firms, Lab Providers Form Genomic Profiling Coalition

Nov 4, 2020

Biocartis to Invest in IVD Partnerships Following Termination of Genomic Health Deal
Premium

Oct 29, 2020

Biocartis, Exact Sciences Terminate Oncotype DX Agreement

Oct 27, 2020

Exact Sciences Aiming to Make Pan-Cancer Blood Screening Part of Standard Medical Care
Premium

Oct 27, 2020

Exact Sciences to Acquire Thrive Earlier Detection for up to $2.15B; Q3 Revenues Spike 87 Percent

Oct 15, 2020

Germany Grants National Reimbursement for Three Additional Breast Cancer Biomarker Tests

Oct 1, 2020

Amid Volatile Markets, GenomeWeb Index Up 3 Percent in September

Sep 25, 2020

People in the News: New Appointments at Inivata, Exact Sciences, Euformatics, More

Sep 24, 2020

Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

Sep 16, 2020

Startup Stitch Bio Bets on CRISPR Tech to Render Cancer Cells With Gene Fusions Druggable
Premium

Aug 28, 2020

XPrize Competition Hopes to Encourage 'Frequent, Fast, Cheap, and Easy' COVID-19 Testing
Premium

Jul 31, 2020

Exact Sciences Positions Itself as Cancer Testing Provider of Future as COVID Crisis Continues
Premium

Jul 30, 2020

Exact Sciences Q2 Revenues Up 35 Percent, Buoyed by COVID-19 Testing Sales

Jun 30, 2020

Oncotype DX Predicts Outcomes in Men With Unfavorable Intermediate-Risk Prostate Cancer, Study Finds
Premium

Breaking News
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.